ResultsIQ › Latest results › Sudeep Pharma Limited

Sudeep Pharma Limited Q1 FY27 earnings call summary

NSE: SUDEEPPHRM · BSE: 544619

Earnings call of 5 Aug 2026, summarised by AI from the filing.

Sudeep Pharma Q1 FY27 revenue grew 27% year-on-year to ₹158.3 cr with EBITDA margin at 34.7%, targeting 37-38% margins.

Key takeaways

Guidance Target to sustain EBITDA margins between 37% and 38%; NSS targeted to deliver margins similar to core specialty by FY28.
Change Phosphoric acid price rose approximately 50% in the quarter; pass-through expected to largely offset input cost impact in Q2.
Driver PFN revenue grew 31% year-on-year, predominantly volume-driven on phosphates scaled with the largest customer.

Original filing on BSE

Sudeep Pharma Limited Q1 FY27 results

As filed: Revenue ₹158 cr, EBITDA ₹54.9 cr, PAT ₹40.6 cr, EBITDA margin 34.7%.

Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹158 cr). Scored once a year-earlier consolidated quarter exists.

Earlier results and the share price after them

Q4 FY26: Revenue ₹182 cr, EBITDA ₹62.6 cr, PAT ₹48.5 cr, EBITDA margin 34.3%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹182 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +26.2% in 29 days (Nifty 500: +2.4%).
Q3 FY26: Revenue ₹172 cr, EBITDA ₹60.0 cr, PAT ₹47.7 cr, EBITDA margin 34.8%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹172 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −8.7% in 28 days (Nifty 500: −4.1%).
Q2 FY26: Revenue ₹163 cr, EBITDA ₹56.0 cr, PAT ₹47.0 cr, EBITDA margin 34.4%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹163 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −14.7% in 28 days (Nifty 500: −0.8%).

Past price moves after results do not indicate future moves. Not a recommendation.

Sudeep Pharma Limited earnings call, investor presentation and press release summaries

Q1 FY27: Earnings call (5 Aug 2026), Results deck (4 Aug 2026), Results deck (4 Aug 2026), Results deck (4 Aug 2026)
Q4 FY26: Earnings call (22 May 2026), Results deck (21 May 2026)
Q3 FY26: Earnings call (9 Feb 2026), Results deck (7 Feb 2026)
Q2 FY26: Earnings call (22 Dec 2025), Results deck (21 Dec 2025)

Figures from the company's filings with NSE and BSE. Not investment advice.